Massachusetts overturns co-pay ban

Share this article:
Tom Sullivan
Tom Sullivan

After three years of wrangling, drug companies can again offer co-pay coupons in Massachusetts.

Governor Deval Patrick put the changes in place when he signed the state's 2013 budget July 8. The co-pay card ban was undone by narrowing a broad 1988 law that barred kickbacks.

“The drug coupons were always seen as falling under this prohibition,” Wells Wilkinson, an attorney with the interest group Community Catalyst, explained. “The legislature left that law intact, but then carved out an exception for co-pay coupons.”

Medicaid and Medicare patients will still be barred from using the discount cards, because the federal programs forbid them.

The Pharmaceutical Care Management Association has been among the groups against co-pay cards, and a 2011 report from the group indicated that overturning the Massachusetts ban would increase the state's prescription costs by $750 million over ten years. Spokesman Charles Cote told MM&M those numbers still hold, and said it was too early to determine what, if any steps the organization would take regarding the new Massachusetts policy.

“They have really kind of set the state up for the increased costs related to the marketing of extensive brand name drugs through these co-pay coupons” Wilkinson said.

“The problem with that line of reasoning is that you're acting as if there's no end benefit for those patients,” Thomas Sullivan, president of the medical education company, Rockpointe, told MM&M. Sullivan said the cards have a clear benefit: patients take their medications and live healthier lives. “All they're focused on is the potential cost,” he added.

This doesn't mean the battle over retail discounts is over. Wilkinson is an attorney for a multi-party lawsuit against eight drug companies which was filed on behalf of groups including the AFSCME District Council 37 Health & Security Plan Trust and the Sergeants Benevolent Association. This lawsuit doesn't rely on Massachusetts' kickback law. Instead, it alleges that the coupons are a form of fraud because they hide the point-of-purchase cost from insurers. This undermines healthcare plans that are calibrated to contain costs, which is another point of contention.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Headliner: HealthSpot's teleconnected CEO

Headliner: HealthSpot's teleconnected CEO

Steve Cashman, Founder and CEO, HealthSpot

Recruitment: The New Breed

Recruitment: The New Breed

What do healthcare agencies really want when it comes to potential employees? The answer to that question is in a constant state of flux, as technologies, clients' changing demands and ...

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the September 2014 issue of MM&M, with all text, charts and pictures.